IMPORTANT INFORMATION

  • CFTR.info is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.

ABBREVIATED TERMS & CONDITIONS

  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.

 

I have read and understood the above

Drug & research development » Clinical trials » NCT00659529

Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease

Official title: The Role of Phosphodiesterase Inhibitors in CF Lung Disease

Clinical Trials gov number: NCT00659529

Click on the tabs to move through the sequence.

Purpose: To determine whether sildenafil can decrease inflammation in CF lung disease.

Phase: 1

Type: Interventional, open-label, single group assignment

Study sponsor: National Jewish Health; Cystic Fibrosis Foundation Therapeutics

  • Confirmed diagnosis of CF based on the following criteria:

– Positive sweat chloride ≥60mEq/liter (by pilocarpine iontophoresis) and/or

– Genotype with two identifiable mutations consistent with CF, and accompanied by ≥1 clinical feature(s) consistent with the CF phenotype

  • FEV1 ≥50% predicted (Knudson) 31
  • Clinically stable without evidence of acute upper or lower respiratory tract infection or current pulmonary exacerbation within the 14 days prior to the screening visit
  • Ability to reproducibly perform spirometry (according to ATS criteria)
  • Ability to produce at least 1mL of sputum spontaneously, or be willing to undergo sputum induction
  • Ability to understand and sign a written informed consent or assent and comply with the requirements of the study
  • Chronic bacterial colonization (3 documented positive cultures in the prior 2 years of which at least one was obtained in the 3 months prior to randomization)

Intervention
Sildenafil

Geographical Location
United States

Number of Participants
≤50 (≥14 years)

Primary Endpoint

Sputum elastase

Secondary Endpoint

  • Exhaled breath condensate pH
  • CF Questionnaire-Revised
  • Serum sildenafil levels

Click on the tabs to move through the sequence.

  • Experimental: 1

All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.

Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.

Link:

http://www.ncbi.nlm.nih.gov/pubmed/17586695

Reference:

Poschet JF, Timmins GS, Taylor-Cousar JL, Ornatowski W, Fazio J, Perkett E, Wilson KR, Yu HD, de Jonge HR, Deretic V. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment  of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol.  2007 Sep;293(3):L712-9. Epub 2007 Jun 22. PubMed PMID: 17586695.

View Trial Results